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ABSTRACT 
It has been demonstrated that monoallelic PALB2 (Partner and Localizer of BRCA2) gene 
mutations predispose to familial breast cancer. Some of the families reported with germline 
PALB2 mutations presented male breast cancer as a characteristic clinical feature. Therefore, 
we wanted to investigate the contribution of germline PALB2 mutations in a set of 131 Spanish 
BRCA1/BRCA2-negative breast/ovarian cancer families with at least one male breast cancer 
case. The analysis included direct sequencing of all coding exons and intron/exon boundaries 
as well as a Multiplex Ligation-dependent Probe Amplification-based analysis of genomic 
rearrangements.  For the first time we have identified a genomic rearrangement of PALB2 
gene involving a large deletion from exon 7 to 11 in a breast cancer family. We have also 
identified several PALB2 variants, but no other obvious deleterious PALB2 mutation has been 
found. Thus, our study does not support an enrichment of PALB2 germline mutations in the 
subset of breast cancer families with male breast cancer cases. The identification of intronic 
and exonic variants indicates the necessity of assessing the implications of variants that do not 
lead to PALB2 truncation in the pathoghenicity of the PALB2 gene. 
 
Keywords: Familial breast cancer; PALB2; Male Breast Cancer; genomic rearrangement; 
BRCA1/BRCA2-negative families, in silico analysis 
 
 
INTRODUCTION 
 
Breast cancer with an autosomal dominant pattern of inheritance accounts for 5-10% of all 
breast cancer cases. Between 20-25% of inherited  breast cancer can be traced to germline 
mutations in BRCA1 and BRCA2 genes. Other genes participating in DNA damage response 
pathways such as CHEK2, ATM and FANCJ/BRIP1 are also involved in familial breast cancer [1]. 
The PALB2 (for “partner and localizer of BRCA2”) gene encodes a protein that 
participates in genome maintenance through double strand break repair. PALB2 protein binds 
to the BRCA2 N-terminal end stabilizing it in key nuclear structures, which allows BRCA2 to 
function in DNA repair and at the S-phase checkpoint [2]. PALB2 co-localizes with BRCA2 being 
essential for key BRCA2 nuclear caretaker functions, implying that PALB2 could be also 
considered a tumor-suppressor gene [3]. Recent studies have shown that PALB2 not only 
interplay with BRCA2, but also mediates the interaction between BRCA1 and BRCA2 in the 
DNA-damage response [4]. BRCA1 acts in this complex as an upstream regulator of PALB2 and 
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BRCA2 in the DNA-damage response and is important for targeting PALB2 and BRCA2 to DNA-
damage sites [4]. PALB2 and BRCA2 act together to deliver RAD51, another DNA double strand 
break repair, to the chromosomal lesion in order to initiate DNA repair. Moreover, it has been 
recently shown that PALB2 binds DNA and physically interacts with RAD51 exerting a 
stimulatory effect on the ability of RAD51 to make D-loops [5]. 
BRCA2 is also known as FANCD1, which is a Fanconi anemia protein. Biallelic mutations 
in BRCA2 and PALB2, respectively, underlie Fanconi anemia complementation groups FA-D1 
and FA-N. However, clinical phenotype of these patients is strikingly different from that 
reported in classical Fanconi anemia [6]. In particular, FA-D1 and FA-N are associated with 
higher risks of solid childhood malignancies such as Wilms tumor and medulloblastoma, which 
occur very rarely in other subtypes of Fanconi anemia. Monoallelic PALB2 mutations have also 
been confirmed to cause moderate-penetrance breast cancer susceptibility [2], accounting for 
about 1% of BRCA1/BRCA2 negative familial and early breast cancer [7][8][9]. PALB2 is 
responsible for 1-2% of young breast cancer patients unselected for breast family history in 
Chinese and white South African populations [10] [11]. None of the breast cancer cases with 
PALB2 germline mutations reported to date have been found to show loss of hererozygosity 
(LOH) at this locus. This lack of LOH has raised speculation on alternative mechanisms of PALB2 
functional inactivation [7]. 
To date, studies examining PALB2 gene in specific populations have been carried out, 
identifying recurrent mutations such as c.2323C>T (p.Q775X) in French Canadians [9], 
c.1592delT (p.L531fs) in Finnish [12] or c.751C>T (p.Q251X) in Chinese population [10]. 
Recently, a potential connection between PALB2 truncating mutations and male breast 
cancer arose from several studies. Rahman et al. (2007)[6] detected that the prevalence of 
truncating mutations was higher in families with both male and female breast cancer (6.7%) 
than in families with only breast cancer cases in females (1%). Moreover, more recently Garcia 
et al. (2009)[7] analyzed PALB2 germline mutations in a cohort of 95 BRCA1/BRCA2-negative 
Spanish breast/ovarian cancer families, identifying only one frameshift alteration 
(c.1056_1057delGA; p.K353IfsX7). Interestingly, the mutation was detected in a family with a 
male breast cancer, further supporting that male breast cancer is a clinical characteristic 
feature of PALB2 autosomal dominant breast cancer syndromes. 
 
The present study attempts to evaluate for the first time in the Spanish population, the 
contribution of germline PALB2 mutations in 131 BRCA1/BRCA2-negative high-risk 
breast/ovarian cancer families with at least one case of male breast cancer. 
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MATERIAL AND METHODS 
 
Patients 
Index cases from 131 BRCA1/BRCA2 mutation-negative Spanish high-risk breast/ovarian cancer 
families with at least one male breast cancer case were screened for mutations within the 
entire coding sequence and splicing sites of PALB2 gene. Families were ascertained through 12 
different Spanish centres (Supplementary Table 1). Clinical characteristics of the families are 
represented in Table 1. The ethics committee approvals as well as informed consent from the 
patients were obtained for the study. 
All index cases had been previously screened for point mutations and large rearrangement 
mutations in BRCA1 and BRCA2 genes and were found to be negative. 
 
Mutation analysis of PALB2 gene 
DNA samples were obtained from peripheral blood leukocytes using standard procedures. The 
entire coding sequence of PALB2 along with flanking intron boundaries were amplified using 
primers designed with Primer3 software (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi). Primer sequences and melting temperatures are shown in 
Supplementary table 2. A negative control was used in each PCR. PCR quality was checked on 
Agilent 2100 Expert Bioanalyzer (Agilent Technologies Inc. Santa Clara, CA USA). Then, PCR 
products were purified by “Exosap-it” (USB Corporation, Cleveland, Ohio) and bi-directional 
sequencing reaction was performed with “Big Dye Terminator v3.1 Cycles Sequencing Kit” 
(Applied Byosistems, Warrington, UK) on ABI PRISM 3730xl Genetic Analyzer (Applied 
Biosystems, Foster City, CA, USA) in accordance with the manufacturer’s instructions. 
Sequences were performed using the PCR primers with the exception of exon 13 (see 
supplementary table 2). Sequences were examined using Staden Package software (Open 
Source Technology Group, Inc). 
Multiplex ligation-dependent probe amplification (MLPA) to detect genomic 
rearrangements of PALB2 was performed using the FANCD2-PALB2 kit (P057) from MRC-
Holland (Amsterdam, The Netherlands) in accordance with the manufacturer’s protocol. The 
samples were run and analyzed on the ABI PRISM 3730xl Genetic Analyzer (Applied 
Biosystems) using fragment analysis tools. Analysis was repeated using an independent sample 
in an independent assay for positive DNA samples of a genomic rearrangement. Analysis of 
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MLPA results was performed visually and by Coffalyser MLPA-DAT from MRC-Holland using 
direct analysis as analysis method to normalization. 
 
In silico analysis 
Briefly, splicing predictions were performed with SpliceSiteFinder [13], MaxEntScan [14], 
NNSplice [15] and GeneSplicer [16] algorithms. Biological significance was suspected only if 
two algorithms predicted a splice site score variation greater than 10% [17]. Amino acid 
substitutions were tested with PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), SIFT 
(http://sift.jcvi.org/) and Align-GVGD (http://agvgd.iarc.fr/) tools. All in silico analysis were 
performed using Alamut- Mutation Interpretation Software v.1.54 (http://www.interactive-
biosoftware.com/alamut.html). 
 
Nomenclature and databases 
Sequences used for PALB2 nomenclature were obtained from the NCBI RefSeq database 
(NG_007406.1 for genomic, NM_024675.3 for mRNA and NP_078951.2 for protein) 
(http://www.ncbi.nlm.nih.gov)). The nomenclature follows the recommendations from the 
Human Genome Variation Society (HGVS, www.hgvs.org/mutnomen/) [18]. 
 
 
RESULTS 
We sequenced all exons and intronic boundaries of PALB2 gene and we also carried out MLPA 
analysis in 131 index cases from BRCA1/BRCA2-negative high-risk Spanish breast/ovarian 
cancer families with at least one male breast cancer. 
We identified a large deletion spanning from exon 7 to 11 (c.2587-?_3201+?del) 
(Figure 1), in a woman diagnosed with breast cancer at 70 years of age. The proband had a 
brother diagnosed both with breast cancer at 75 years and gastric cancer after the initial 
breast cancer diagnosis (Figure 2). To confirm segregation with disease, we tested for the 
presence of the PALB2 deletion in the paraffined breast tumoral sample of the affected 
brother. MLPA analysis demonstrated the presence of the alteration. Interestingly, we 
observed a dosage reduction close to 75% for exons 7 to 11 together with a dosage reduction 
in the 25%-50% range for the remaining exons (the only exception being exon1, in which no 
dosage reduction was observed). The data might be compatible with partial loss of the wild 
type allele (exons 2 to 13) in the tumor (Figure 1).  
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In addition to this deletion, we also identified seventeen PALB2 germline variants, 
although none of them was predicted to result in a truncated protein product (Table 2). Seven 
of them were novel (c.-200-27T>G; c.-158G>T; c.620C>G (p.Pro207Arg); c.1684+29A>G; 
c.2586+58C>T; c.2587-38C>G; c.2865T>A (p.Ser955Arg)) and all of them except c.2586+58C>T 
were found once in our samples. The variants c.-47G>A, c.212-58A>C, c.1010T>C 
(p.Leu337Ser), c.1194G>A (p.=),  and c.1572A>G (p.=), c.1676A>G (p.Gln559Arg), c.2014G>C 
(p.Glu672Gln), c.2590C>T (p.Pro864Ser), c.2993G>A (p.Gly998Gln) and c.3300T>G (p.=) had 
been previously reported [7, 10, 12, 19-23].  
The results of bioinformatic predictions for intronic and missense variants are 
represented in Table 3. Interestingly, three of the missense variants, c.620C>G (p.Pro207Arg), 
c.1010T>C (p.Leu337Ser), and c.2993G>A (p.Gly998Gln), were predicted to likely affect PALB2 
protein function by all the tested algorithms. Unfortunately, it was not possible to do 
segregation analysis in the families for any of these variants. The bioinformatic splicing 
analyses do not show variations in the consensus site scores. For variants c.-200-27T>G, c.-
47G>A, c.1676A>G (p.Gln559Arg), and c.2590C>T (p.Pro864Ser), a reduction of 100% in a 
cryptic splice site score is predicted for at least two algorithms. MaxEntScan and NNSplice 
algorithms predicted an increase in the score of the cryptic site c.2597 in 11.2 and 22.8%, by 
the variant c.2590C>T (p.Pro864Ser). 
There were six index cases sharing six different variants: c.212-58A>C, c.1676A>G 
(p.Gln559Arg), c.2014G>C (p.Glu672Gln), c.2586+58C>T, c.2993G>A (p.Gly998Gln) and 
c.3300T>G (p.=). The variants c.1676A>G (p.Gln559Arg) and c.2586+58C>T were also present in 
other cases, and the former is predicted by the bioinformatic software to probably affect 
PALB2 protein function. In order to identify if these six variants were inherited together, co-
segregation analysis in one of the carrier families was performed. Our results suggest that all 
the six variants constituted a haplotype (Supplementary figure 1) that is present in the two 
breast cancer patients of the analyzed family. 
 
DISCUSSION 
PALB2 mutations have recently been shown to confer a moderate risk to develop breast 
cancer [6]. It has been reported that families carrying protein-truncating PALB2 mutations 
shown cases of male breast cancer [6, 7]. Given the increased risk of male breast cancer 
associated with carrying a germline BRCA2 mutation and the functional relationship between 
BRCA2 and PALB2, the male PALB2 mutation carriers might be at an increased risk of breast 
cancer. 
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Until now more than 26 PALB2 truncating mutations have been reported [20, 22, 24-
26], 22 of them found in breast cancer families. Although large genomic rearrangements in 
PALB2 have been analysed in studies of familial breast cancer [9, 20, 27, 28], the unique large 
genomic mutation detected in PALB2 was c.71-?_561+?del. This genomic change was 
identified in a Fanconi Anemia patient, and it implies the deletion of exons 2, 3 and 4 [29]. In 
our series of 131 index cases from Spanish BRCA1/BRCA2-negative breast/ovarian cancer 
families with a male breast cancer case, we identified a large rearrangement in one breast 
cancer index case. The mutation c.2587-?_3201+?del detected in our population is a large 
deletion comprising exons 7 to 11. Our finding provides the first evidence that large genomic 
changes in PALB2 also contribute to hereditary breast cancer in families BRCA1/BRCA2 
negatives. 
To date, all PALB2 mutations reported as pathogenic result in premature protein 
truncation [6], and were identified in about 1% of familial breast cancer. In breast cancer 
families with both female and male breast cancer cases, frequency of PALB2 mutations 
increased to 6.7% (1/15) in the UK series of Rahman et al [6] and to 9% (1/11) in the Spanish 
series of Garcia et al [7]. Although these previous series of families with male breast cancer 
were small, results seemed to suggest a higher implication of PALB2 mutations within this type 
of families. In the present study, we analysed 131 Spanish female and male breast cancer 
families extending the mutation detection analysis to detect large genomic rearrangements of 
PALB2 by using Multiplex ligation-dependent probe amplification (MLPA).The frequency of 
PALB2 mutations found was 0.75%, which is similar to the 1% frequency previously reported 
for breast cancer families not selected for male breast cancer. However, we cannot rule out 
the potential pathogenicity of non truncating PALB2 variants. It has been shown that the N-
terminal coiled-coil motif of PALB2 (residues 1-319) interacts with the coiled-coil domain of 
BRCA1 [4, 30], whereas the C-terminal WD40 repeats of PALB2 (residues 836-1186) associate 
with the N-terminus of BRCA2 [3, 4, 31]. Thus, PALB2 missense variants in these domains might 
be pathogenic. From the missense variants identified in our study, c.620C>G (p.Pro207Arg) is 
located in the coiled-coil domain of PALB2, whereas c.2590C>T (p.Pro864Ser), c.2865T>A 
(p.Ser955Arg) and c.2993G>A (p.Gly998Gln) are located in the C-terminal domain of the 
protein. Moreover variants c.620C>G (p.Pro207Arg), c.1010T>C (p.Leu337Ser), and c.2993G>A 
(p.Gly998Gln) have been predicted as pathogenic by the three amino acidic algorithms (Table 
3). 
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As for other genes, the possibility of intronic variants of PALB2 being implicated in the 
splicing process should not be discarded. Besides, functional analysis for variants that could 
regulate gene expression should also being considered. 
 
The MLPA analysis of the breast tumor sample FFPE tissue from the carrier of exon 7-11 
deletion suggests partial loss of the wild type PALB2 allele (exons 2 to 13) which in turns could 
support previous evidences that PALB2 loss of function might also conform to the inactivation 
model of a classic tumor-suppressor gene [7]. Yet, great caution should be taken when 
interpreting MLPA analysis of FFPE tissue 
 
In summary, our work identifies for the first time a genomic rearrangement of PALB2 gene in a 
BRCA1/BRCA2 mutation-negative Spanish cancer family with at least one male breast cancer 
case. If we considered only PALB2 truncation variants as pathogenic, the frequency of PALB2 
mutations in high-risk families with male breast cancer is similar to that reported for high-risk 
families not selected by the presence of male breast cancer. However, more studies to assess 
the implication of PALB2 variants that do not originate PALB2 truncation (missense changes, 
small in-frame insertions or deletions and potential splice site alterations) are required. 
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Table 1. Clinical charactheristics of the 131male and female breast cancer index cases 
Clinical diagnosis and patient information 
Age in years at first diagnosis (years)(male/female)     58/55 
Breast cancer (male/female)       83/36 
Bilateral breast cancer (male/female)      5/4 
Ovarian cancer         3 
Family history of first degree relative with breast cancer (male/female)  40/77 
Family history of second degree relative with breast cancer (male/female)  18/44 
Other malignancies in family       
Gastric         21 
 Colon         17 
Prostate         16 
Lung         7 
Ovarian         6 
Leukaemia        5 
Melanoma        5 
Cerebral         4 
Larynx         3 
 Kidney         3 
Stomach        2 
Pancreas        2 
Osteosarcoma        2 
 Bladder         2 
 Throat         1 
 Uterus         1 
 Lymphoma        1 
 Non- Hodgkin Lymphoma       1 
 Esophagus        1 
 Lips         1 
Cervix         1 
Head-neck        1 
Multiple malignancies 
 Breast and prostate cancer      5 
 Breast and gastric cancer       3 
 Breast cancer and melanoma      2 
 Breast and colon cancer       2 
 Breast and ovarian cancer       1 
 Larynx and stomach cancer      1 
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Table 2. PALB2 sequence variants identified in 131 Spanish breast/ovarian cancer families with male breast cancer cases 
 
 
 
 
 
 
 
 
 
 
 
 
 
a In bold variants not previously reported 
b Allelic frequency is the percentage of n/N, where n is the number of times of minor allele and N is the total of alleles. 
 
 
Location Nucleotide changea Protein change Name of SNP 
Genotypes Allelic frequency (%)b 
AA AB BB A (A%) B (B%) 
5’ upstream sequence c.-200-27T>G - - 0 1 130 1 (0.38) 261 (99.62) 
EXON1 
c.-158G>C - - 0 1 130 1 (0.38) 261 (99.62) 
c.-47G>A - rs8053188 0 3 128 3 (1.14) 259 (98.86) 
IVS3 c.212-58A>C - - 0 6 125 6 (2.29) 256 (97.71) 
EXON 4 
c.620C>G p.Pro207Arg - 0 1 130 1 (0.38) 261 (99.62) 
c.1010T>C p.Leu337Ser rs45494092 0 3 128 3 (1.14) 259 (98.86) 
c.1194G>A p.Val398Val rs61755173 0 1 130 1 (0.38) 261 (99.62) 
c.1572A>G p.Ser524Ser rs45472400 0 1 130 1 (0.38) 261 (99.62) 
c.1676A>G p.Gln559Arg rs152451 4 34 93 42 (16.03) 220 (83.97) 
IVS4 c.1684+29A>G - - 0 1 130 1 (0.38) 261 (99.62) 
EXON 5 c.2014G>C p.Glu672Gln rs45532440 0 6 125 6 (2.29) 256 (97.71) 
IVS6 
c.2586+58C>T - rs249954 7 60 64 74 (28.24) 188 (71.76) 
c.2587-38C>G - - 0 1 130 1 (0.38) 261 (99.62) 
EXON 7 c.2590C>T p.Pro864Ser rs45568339 0 2 129 2 (0.76) 260 (99.24) 
EXON 9 c.2865T>A p.Ser955Arg - 0 1 130 1 (0.38) 261 (99.62) 
c.2993G>A p.Gly998Gln rs45551636 0 6 125 6 (2.29) 256 (97.71) 
EXON 12 c.3300T>G p.Thr1100Thr rs45516100 0 6 125 6 (2.29) 256 (97.71) 
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Table 3. Results of bioinformatic analysis for PALB2 variants 
VARIANT PROTEIN CHANGE 
PREDICTION AMINO ACIDIC 
CHANGE SPLICE SIGNAL DETECTION 
POLYPHEN SIFT A-GVGD 
Sitea 
SSF [0-100] MaxEnt [0-12] NNSPLICE [0-1] GeneSplicer [0-15] 
Consensus 
splice site 
score 
Consensus 
splice 
mutation 
scoreb 
Predicted 
variation of 
Cryptic Site 
Position and 
Scorec 
 
Consensus 
splice site 
score 
Consensus 
splice 
mutation 
scoreb 
Predicted 
variation of 
Cryptic Site 
Position and 
Scorec 
 
Consensus 
splice site 
score 
Consensus 
splice 
mutation 
scoreb 
Predicted 
variation of 
Cryptic Site 
Position and 
Scorec 
 
Consensus 
splice site 
score 
Consensus 
splice 
mutation 
scoreb 
Predicted 
variation of 
Cryptic Site 
Position and 
Scorec 
 
c.-200-27T>G - NA NA NA A - -  - -  -  
c.-200-42 
0.89  
(+4.7%) 
- - 
c.200-42 
4.60 
 (+0.2%) 
c.-158G>C - NA NA NA A - -  - -  - -  - -  
c.-47G>A - NA NA NA A - - 
c.-46 
74.92 
 (-100%) 
- - c.-46 5.71 (-100%) - -  - -  
c.212-58A>C - NA NA NA A 90.34 90.34  10.02 10.02  0.98 0.98  7.88 7.92 (+0.4%)  
c.620C>G p.Pro207Arg Probably damaging 
Affect 
protein 
function 
Class 
C65 A 90.34 90.34 
c.623 
79.40 
(-100%) 
10.02 10.02 
c.623 
 0.27 
(-94.9%) 
0.98 0.98  7.88 7.88  
c.1010T>C p.Leu337Ser Possibly damaging 
Affect 
protein 
function 
Class 
C65 
A 90.34 90.34  10.02 10.02  0.98 0.98  7.88 7.88  
D 87.54 87.54  8.88 8.88  0.99 0.99  0.75 0.75  
c.1194G>A p.Val398Val NA NA NA 
A 90.34 90.34  10.02 10.02  0.98 0.98  7.88 7.88  
D 87.54 87.54  8.88 8.88  0.99 0.99  0.75 0.75  
c.1572A>G p.Gln559Arg Benign Tolerated Class C35 D 87.54 87.54  8.88 8.88  0.99 0.99  0.75 0.75  
c.1676A>G p.Gln559Arg Benign Tolerated Class C35 D 87.54 87.54 
c.1679 76.25 
(-1.1%) 8.88 8.88 
c.1679 
 0.04 
(-100%) 
0.99 0.99  0.75 0.82 (+8.2%)  
c.1684+29A>G - NA NA NA D 87.54 87.54  8.88 8.88  0.99 0.99  0.75 1.18 (+56.9%)  
c.2014G>C p.Glu672Gln Benign 
Affect 
protein 
function 
Class 
C25 D 71.73 71.73  7.09 7.09  0.95 0.95  2.36 2.36  
c.2586+58C>T - NA NA NA D 84.48 84.48  6.80 6.80  0.81 0.81  - -  
c.2587-38C>G - NA NA NA A 75.57 75.57  3.31 3.31  - -  - -  
c.2590C>T p.Pro864Ser Probably damaging Tolerated 
Class 
C65 A 75.57 75.57  3.31 3.31 
c.2597 
 1.89 
(+11.2%) 
- - 
c.2597 
 0.65 
(+22.8%) 
- -  
c.2865T>A p.Ser955Arg Benign 
Affect 
protein 
function 
Class 
C65 A 77.22 77.22  8.14 8.14  0.54 0.54  2.70 2.62(-2.9%)  
c.2993G>A p.Gly998Gln Probably damaging 
Affect 
protein 
function 
Class 
C65 D 85.40 85.40  9.21 9.21  0.99 
1.00 
(+1.0%)  0.85 
1.31 
(+54.4%)  
c.3300T>G p.Thr1100Thr NA NA NA D 100.0 100.0  - -  - -  - -  
- No predicted Donor or Aceptor site 
a D=Donor site; A=Aceptor site 
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b Variations in consensus splice sites are represented by its new score and in case of variation, the percentage of variation in parenthesis 
C Indicated are cryptic splice sites for which at least two algorithms predicted a splice site score variation, and in parenthesis the percentage of variation 
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LEGENDS 
 
Figure 1. Bar charts of MLPA results. A: Profile of a normal control. B: Profile of the patient 
with the heterozygous deletion of exons 7-11 of PALB2 gene. C: Profile of a paraffine tumor 
sample from male with BC relative of the PALB2 index case, also carrying the deletion. The grey 
bars represent the exons with the deletion. 
Figure 2. Pedigree of the breast cancer family carrying the c.2587-?_3201+?del PALB2 
mutation. Cancer diagnoses are indicated in those affected patients; in brackets the age at 
diagnosis or exitus. The arrow indicates the index case analysed. PALB2 mutation carriers are 
indicated by the + sign. BiBC: bilateral breast cancer, GC: gastric cancer  
Supplementary figure 1. Co-segragation analysis of variants c.212-58A>C, c.1676A>G, 
c.2014G>C, c.2586+58C>T, c.2993G>A, c.3300T>G in one of the six carriers families. Individuals 
analysed are indicated by + and – signs: carriers of all the six variants in heterozygous state are 
indicated with a + sign, individuals that were not carriers of any of the variants are indicated 
with a - sign. *One family member was heterozygous for variants c.1676A>G and 
c.2586+58C>T, only. Cancer diagnoses are indicated in the affected patient; in brackets the age 
at diagnosis or the actual age of the individual.  
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Supplementary table 1. Participating centres and families from Spain 
Center/Hospital Number of families 
Hospital Universitario San Carlos (Madrid) 27 
Hospital Universitari Vall d’Hebron (Barcelona) 14 
Hospital de la Santa Creu i Sant Pau (Barcelona) 13 
Fundación Pública Galega de Medicina Xenómica 
(Galicia) 
12 
Institut Català d’Oncologia 11 
Hospital Infantil Miguel Servet (Zaragoza) 11 
CNIO (Madrid) 10 
Instituto de Biología y Genética Molecular (UVa-CSIC, 
Valladolid) 
10 
Hospital Universitario La Fe (Valencia) 10 
Hospital Sant Joan (Reus) 8 
Hospital de Cruces (Barakaldo) 4 
Hospital Universitario Central de Asturias 1 
Total 131 
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Supplementary table 2. Sequences of  PALB2 primers used for amplification and sequencing, 
lenght of the amplicon and melting temperature. 
PCR-fragment Sequence Length Melting Temperature (ºC) 
EXON 1 
F-CAGAGATTCCGGCTACTTCC 
450 56 
R-GACACAAAGCCAGGCCTAAA 
EXONS 2&3 
F-GTGCTACTCCCTGCCTCTTG 
470 56 
R-CACACTGTGGGAAAAAGAACAA 
EXON 4 
F-GAACACATTCCTCCTAAAGGTAACA 
750 58 
R-GGAACTGTAGTCGCCCTGGT 
F-CAGAACCAGTTACAGAAATTAATGAAG 
714 56 
R-TTGCATCCTTATTTTTATTTTTAAACC 
F-TAGCCTGGAAGCAACCTCTC 
717 58 
R-TTGAGCCAGGGTCTCACTCT 
EXON 5 
F-GAAGCTCACTCTTTGTTGGGTA 
614 56 
R-GTATGCTGGCTTTGCGAGTT 
F-CGCATGGATACAGAAATGGA 
653 56 
R-TCAAAGAAACACGTCAAACCA 
EXON 6 
F-GTTTGCATTTGGAGCTTTGC 
300 56 
R-TAAAGAACAAGAAGCTATATGACTGAA 
EXON 7 
F-GCTCTTTCTTTTCACCTGCAT 
398 56 
R-GCATGGTCATAGCTCCCAAT 
EXON 8 
F-TCCTTGTACAGTGAGAATACAAAAGAA 
260 56 
R-TGCACTTAAAACCAGCTGACA 
EXON 9 
F-AAAAGGTTACTCCTCACATCACC 
321 56 
R-ATTACACCCCCAGCACAGAA 
EXON 10 
F-CAGTTCAACAATGCGGAGAA 
328 56 
R-CAACAGCAACACAAAACCACA 
EXON 11 
F-TTTCCCTGGTCACCTCCTAA 
290 56 
R-CGGGGAAGGTTTGTTCATTA 
EXON 12 
F-GAGCCTATCGGTCATTGCTT 
361 56 
R-TTTTCCATTCTTCTAAGTGACACAA 
EXON 13 
F-TGGTTTTGGGAACATGGTTT† 
714 56 F- CCTGGAAGGTGACGTGAAAG* 
R-TGAAATTTACACTTACTAGGCAAAGA 
†Primer used only for amplification 
*Primer used only for sequencing 
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